TrialAnnals of the rheumatic diseases2012

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

Joachim Sieper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.